KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: Two novel mutations and selective occurrence in leukemia subtypes and age groups

Experimental and Molecular Pathology

Volumn 85, Issue 3, 2008, Pages 227-231

  Sritana, Narongrit ^a   Auewarakul, Chirayu U ^a,b  

^a CHULABHORN RESEARCH INSTITUTE   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute myeloid leukemia; FLT3; Immunophenotypes; KIT; Novel mutations; Receptor tyrosine kinase

Indexed keywords

CD135 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; PROTEIN KIT; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SOUTHEAST ASIA;

AGE DISTRIBUTION; BASE SEQUENCE; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; FMS-LIKE TYROSINE KINASE 3; GENOTYPE; HUMANS; INCIDENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; THAILAND;

EID: 56549117415     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.09.004     Document Type: Article

References (21)

1. Auewarakul C.U., Sritana N., Limwongse C., Thongnoppakhun W., and Yenchitsomanus P.T. Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet. Cytogenet. 162 2 (2005) 127-134
2. Auewarakul C.U., Lauhakirti D., Promsuwicha O., and Munkhetvit C. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia. Ann. Hematol. 85 2 (2006) 108-112
3. Beghini A., Magnani I., Ripamonti C.B., and Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol. J. 3 3 (2002) 157-163
4. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89 8 (2004) 920-925
5. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C.B., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107 9 (2006) 3463-3468
6. Care R.S., Valk P.J., Goodeve A.C., Abu-Duhier F.M., Geertsma-Kleinekoort W.M., Wilson G.A., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br. J. Haematol. 121 5 (2003) 775-777
7. Corbacioglu S., Kilic M., Westhoff M.A., Reinhardt D., Fulda S., and Debatin K.M. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 108 10 (2006) 3504-3513
8. Doepfner K.T., Boller D., and Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 63 3 (2007) 215-230
9. Gari M., Goodeve A., Wilson G., Winship P., Langabeer S., Linch D., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 105 4 (1999) 894-900
10. Gilliland D.G. Molecular genetics of human leukemias: new insights into therapy. Semin. Hematol. 39 4 Suppl 3 (2002) 6-11
11. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 7 (1998) 2322-2333
12. Growney J.D., Clark J.J., Adelsperger J., Stone R., Fabbro D., Griffin J.D., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106 2 (2005) 721-724
13. Mitelman, F., 1995. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: S. Karker.
14. Nanri T., Matsuno N., Kawakita T., Suzushima H., Kawano F., Mitsuya H., et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 19 8 (2005) 1361-1366
15. Schnittger S., Kohl T.M., Haferlach T., Kern W., Hiddemann W., Spiekermann K., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 5 (2006) 1791-1799
16. Shimada A., Ichikawa H., Taki T., et al. Low frequency of KIT gene mutation in pediatric acute myeloid leukemia with inv(16)(p13q22): a study of the Japanese Childhood AML Cooperative Study Group. Int. J. Hematol. 86 3 (2007) 289-290
17. Steffen B., Muller-Tidow C., Schwable J., Berdel W.E., and Serve H. The molecular pathogenesis of acute myeloid leukemia. Crit. Rev. Oncol. Hematol. 56 2 (2005) 195-221
18. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3 2 (2003) 89-101
19. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 12 (2002) 4326-4335
20. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
21. Wang Y.Y., Zhou G.B., Yin T., Chen B., Shi J.Y., Liang W.X., et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. U. S. A. 102 4 (2005) 1104-1109